… lung adenocarcinoma (n = 186), we uncovered two distinct subgroups of lung adenocarcinoma
… The signature was validated in 4 independent lung adenocarcinoma cohorts, including …

Background: Lung adenocarcinoma (LUAD) is one of the main types of lung cancer.
Because of its low early diagnosis rate, poor late prognosis, and high mortality, it is of great …

… Lung adenocarcinomas (LUAD) is the most common histological subtype of lung cancers.
Tumor immune … This study is aimed to develop a robust immune‐related signature of LUAD. …

… in 189 patients, and we developed a predictive signature. In the validation phase, one
internal cohort and two external cohorts were used to validate our novel prognostic signature. …

… most hypoxic tumours, we aimed to develop a lung adenocarcinoma (LUAD) hypoxia-related …
The 28-gene LUAD hypoxia related signature can be taken forward for further validation …

… cell lung cancer (NSCLC) is the most common type of lung … lung squamous cell carcinoma
and lung adenocarcinoma (… of lung cancer, accounting for approximately 40% of all lung …

… to explore the potential value of autophagy-associated genes in lung adenocarcinoma (LUAD). …
We developed a survival model for LUAD and validated the performance of the model, …

… found to participate in the development and progression of cancer. This present study
aimed to construct a RBP-based prognostic prediction model for lung adenocarcinoma (LUAD). …

One of the most common sites of extra‐thoracic distant metastasis of nonsmall‐cell lung
cancer is the brain. Our study was performed to discover genes associated with postoperative …

… (LUAD) is the most common subtype of non-small cell lung … progression and poor survival
in lung adenocarcinoma, 10–12 no … In addition, we validated the prognostic value of the gene …